Sign up for Table of Contents Alerts.
Email this page
Print this page
Perspectives
Inhibition of VEGF Signaling Pathways in Multiple Myeloma and Other Malignancies
Klaus Podar and Kenneth C. Anderson
volume 6 | issue 5
1 March 2007Pages: 538 - 542
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.
Due to its direct effects on endothelial cells, circulatory endothelial progenitor cells, hematopoietic stem cells, immune cells, osteoclasts, osteoblasts, and neurons, vascular endothelial growth factor (VEGF) is linked to tumor cell development, progression, metastatic osteolysis, and drug resistance, as well as clinical features such as metastatic osteolysis. Importantly, recent advances in the understanding of mechanisms of action of antiangiogenic drugs/ VEGF-inhibitors have fundamentally changed treatment regimens in cancer. VEGF plays a key role not only in solid tumors but also in hematologic malignancies, including multiple myeloma (MM). Despite recent advances in our understanding of MM pathogenesis and novel therapies (bortezomib and lenalidomide), it remains incurable. Our own and others’ work suggest that VEGF-inhibitors e.g. the small-molecule VEGF receptor inhibitor pazopanib, may also improve patient outcome in MM.
Authors
Klaus Podar
Dana-Farber Cancer Institutte, Jerome Lipper Multiple Myeloma Center; Boston MA, USA
Kenneth C. Anderson
Dana-Farber Cancer Institutte, Jerome Lipper Multiple Myeloma Center; Boston MA, USA
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.